Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Meir Daller

Urology Fort Myers, FL Medical Doctor

NPI 1386656528 CMS profile 334686

14320 Metropolis Ave Ste 1, Fort Myers, FL 33912

Open in the dashboard

General payments

$3,087

166 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meir Daller of Fort Myers, FL is reported in the CMS Open Payments database as having received $3,087 across 166 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25 1
2023 General $22 1
2022 General $459 21
2021 General $920 51
2020 General $745 47
2019 General $916 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meir Daller
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Meir Daller were reported at $25. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Meir Daller Urology median Middle half National median
2019 $916 $480 $147–$1,201 $163
2020 $745 $246 $87–$645 $114
2021 $920 $358 $111–$1,000 $132
2022 $459 $476 $143–$1,263 $149
2023 $22 $560 $168–$1,461 $160
2024 $0 $563 $170–$1,464 $164
2025 $25 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Endo Pharmaceuticals Inc. $494 26 payments
  2. Astellas Pharma US Inc $479 22 payments
  3. Antares Pharma, Inc. $433 30 payments
  4. Coloplast Corp $210 10 payments
  5. TOLMAR Pharmaceuticals, Inc. $200 11 payments
  6. C. R. Bard, Inc. & Subsidiaries $170 3 payments
  7. Pfizer Inc. $149 12 payments
  8. Clarus Therapeutics Inc. $128 9 payments
  9. Blue Earth Diagnostics Limited $122 5 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $109 6 payments
  11. Other $593 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,898 159 payments
  2. Education $190 7 payments
Products named General payments · program years 2019–2025
  1. XIAFLEX $494 26 payments
  2. AVEED $469 25 payments
  3. EDEX $469 25 payments
  4. XTANDI $442 29 payments
  5. MYRBETRIQ $358 18 payments
  6. OTREXUP $134 13 payments
  7. NOCDURNA $131 6 payments
  8. XYOSTED $131 6 payments
  9. JATENZO testosterone replacement therapy $128 9 payments
  10. JATENZO testosterone replacement therapy $128 9 payments
  11. Other $1,807 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

166 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record